Enliven therapeutics and imara announce merger agreement

Boulder, co and boston, ma, oct. 13, 2022 (globe newswire) -- enliven therapeutics, inc. (enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and imara inc. (nasdaq: imra) (imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. the combined company will focus on advancing enliven's pipeline of precision oncology product candidates. enliven is advancing two parallel lead product candidates: elvn-001, a highly selective small molecule bcr-abl inhibitor designed to address the challenges that limit the efficacy, tolerability and convenience of currently available adenosine triphosphate (atp)-competitive tyrosine kinase inhibitors (tkis) in the treatment of chronic myeloid leukemia (cml), and elvn-002, a potent, selective and irreversible her2 and pan-her2 mutant kinase inhibitor for the treatment of her2 mutant lung cancer and other her2-driven tumor types. upon completion of the merger, which is subject to approval by imara's and enliven's stockholders, the combined company is expected to operate under the name enliven therapeutics, inc. and trade on the nasdaq global select market under the ticker symbol elvn.
ELVN Ratings Summary
ELVN Quant Ranking